Benutzer: Gast  Login
Titel:

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.

Dokumenttyp:
Clinical Trial; Journal Article; Article
Autor(en):
Steimer, W; Zopf, K; von Amelunxen, S; Pfeiffer, H; Bachofer, J; Popp, J; Messner, B; Kissling, W; Leucht, S
Abstract:
BACKGROUND: Amitriptyline has been replaced in many countries by alternative and more expensive drugs based on claims of improved tolerability and toxicity and despite slightly reduced efficacy. Preliminary studies indicate that adverse effects could be linked to polymorphisms of drug-metabolizing enzymes, but information on their clinical impact remains scanty and includes mainly case reports. We conducted a prospective blinded two-center study seeking correlations between CYP2C19 and CYP2D6 ge...     »
Zeitschriftentitel:
Clin Chem
Jahr:
2005
Band / Volume:
51
Heft / Issue:
2
Seitenangaben Beitrag:
376-85
Sprache:
eng
Volltext / DOI:
doi:10.1373/clinchem.2004.041327
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/15590749
Print-ISSN:
0009-9147
TUM Einrichtung:
Institut für Klinische Chemie und Pathobiochemie; Klinik und Poliklinik für Psychiatrie und Psychotherapie
 BibTeX